HK Stock MarketDetailed Quotes

02607 SH PHARMA

Watchlist
  • 13.000
  • +0.240+1.88%
Market Closed Nov 29 16:08 CST
48.16BMarket Cap10.79P/E (TTM)

SH PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Turnover
6.14%209.63B
5.14%139.41B
5.93%70.15B
12.21%260.3B
13.11%197.51B
18.70%132.59B
16.39%66.23B
7.49%231.98B
8.47%174.61B
6.15%111.71B
Operating income
6.14%209.63B
5.14%139.41B
5.93%70.15B
12.21%260.3B
13.11%197.51B
18.70%132.59B
16.39%66.23B
7.49%231.98B
8.47%174.61B
6.15%111.71B
Operating expenses
-7.44%-186.45B
-6.67%-123.25B
-7.87%-62.12B
-13.63%-228.97B
-14.22%-173.55B
-19.50%-115.53B
-16.19%-57.59B
-7.59%-201.49B
-9.10%-151.93B
-5.98%-96.68B
Gross profit
-3.28%23.18B
-5.22%16.17B
-7.03%8.03B
2.76%31.33B
5.67%23.96B
13.51%17.06B
17.80%8.63B
6.81%30.49B
4.45%22.68B
7.26%15.03B
Selling expenses
9.46%-9.48B
15.10%-6.57B
15.86%-3.29B
2.64%-13.9B
-1.29%-10.47B
-13.81%-7.73B
-18.05%-3.91B
-7.22%-14.28B
-1.18%-10.34B
-7.42%-6.79B
Administrative expenses
1.22%-4.14B
-3.86%-2.87B
-0.90%-1.39B
-14.43%-5.71B
-11.62%-4.19B
-19.00%-2.76B
-15.70%-1.38B
2.95%-4.99B
-5.09%-3.76B
0.03%-2.32B
Research and development expenses
-10.09%-1.62B
-7.67%-1.11B
7.26%-501.45M
-4.35%-2.2B
-5.70%-1.47B
-26.76%-1.03B
-20.82%-540.69M
-6.29%-2.11B
-1.63%-1.39B
7.99%-809.67M
Profit from asset sales
39.44%145.83M
88.91%139.31M
405.21%110.04M
-93.57%92.48M
-92.67%104.58M
-94.83%73.75M
188.72%21.78M
2,368.58%1.44B
22,234.19%1.43B
23,988.34%1.43B
Revaluation surplus
-40.51%142.2M
-41.94%114.29M
-41.55%52.25M
85.03%404.73M
225.04%239.02M
675.23%196.84M
240.65%89.4M
206.18%218.74M
141.65%73.54M
171.34%25.39M
-Changes in the fair value of other assets
-40.51%142.2M
-41.94%114.29M
-41.55%52.25M
85.03%404.73M
225.04%239.02M
675.23%196.84M
240.65%89.4M
206.18%218.74M
141.65%73.54M
171.34%25.39M
Impairment and provision
-89.25%-496.97M
-22.04%-329.78M
-42.34%-241.8M
-30.64%-841.24M
-15.91%-262.6M
-51.60%-270.22M
-362.28%-169.87M
-360.73%-643.93M
13.13%-226.55M
3.90%-178.24M
-Other impairment is provision
-89.25%-496.97M
-22.04%-329.78M
-42.34%-241.8M
-30.64%-841.24M
-15.91%-262.6M
-51.60%-270.22M
-362.28%-169.87M
-360.73%-643.93M
13.13%-226.55M
3.90%-178.24M
Special items of operating profit
96.95%682.34M
124.15%384.1M
-34.56%233.27M
-21.78%725.04M
-49.72%346.45M
-61.50%171.36M
41.47%356.49M
-59.88%926.88M
-67.03%689.04M
-76.12%445.11M
Operating profit
1.40%7.82B
3.86%5.54B
-4.11%2.79B
-11.38%9.15B
-10.54%7.71B
-17.32%5.33B
23.59%2.91B
9.28%10.33B
11.48%8.62B
11.00%6.45B
Financing cost
0.45%-1.15B
8.70%-705.94M
10.46%-374.43M
-13.14%-1.49B
-15.71%-1.15B
-19.16%-773.22M
-16.64%-418.18M
-5.45%-1.31B
-7.26%-997.59M
-12.10%-648.91M
Special items of earning before tax
34.01%-24.39M
63.46%-8.88M
54.93%2.02M
-197.11%-612.94M
30.84%-36.96M
41.10%-24.29M
115.24%1.3M
-234.51%-206.3M
-1,031.28%-53.44M
-228.25%-41.24M
Earning before tax
1.92%6.64B
6.36%4.82B
-3.02%2.42B
-19.91%7.05B
-13.86%6.52B
-21.26%4.53B
25.44%2.49B
8.16%8.81B
11.35%7.57B
10.36%5.76B
Tax
-3.57%-1.62B
-9.66%-1.22B
-2.28%-551.13M
-3.93%-1.89B
1.16%-1.57B
6.45%-1.12B
-18.63%-538.85M
2.83%-1.82B
-10.54%-1.58B
-13.39%-1.19B
After-tax profit from continuing operations
1.40%5.02B
5.28%3.6B
-4.48%1.87B
-26.11%5.17B
-17.22%4.95B
-25.14%3.42B
27.46%1.95B
11.43%6.99B
11.56%5.98B
9.59%4.56B
Earning after tax
1.40%5.02B
5.28%3.6B
-4.48%1.87B
-26.11%5.17B
-17.22%4.95B
-25.14%3.42B
27.46%1.95B
11.43%6.99B
11.56%5.98B
9.59%4.56B
Minority profit
-16.24%969.12M
-18.80%655.45M
-25.75%323.29M
1.72%1.4B
-1.14%1.16B
-7.07%807.18M
54.77%435.4M
16.41%1.37B
33.04%1.17B
45.49%868.61M
Profit attributable to shareholders
6.78%4.05B
12.72%2.94B
1.62%1.54B
-32.92%3.77B
-21.13%3.8B
-29.38%2.61B
21.31%1.52B
10.28%5.62B
7.35%4.81B
3.58%3.7B
Basic earnings per share
5.83%1.09
11.27%0.79
2.44%0.42
-36.65%1.02
-28.97%1.03
-37.17%0.71
-6.82%0.41
-10.06%1.61
-8.23%1.45
-10.32%1.13
Diluted earnings per share
5.83%1.09
11.27%0.79
2.44%0.42
-36.65%1.02
-28.97%1.03
-37.17%0.71
-6.82%0.41
-10.06%1.61
-8.23%1.45
-10.32%1.13
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
Auditor
--
--
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
--
PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Turnover 6.14%209.63B5.14%139.41B5.93%70.15B12.21%260.3B13.11%197.51B18.70%132.59B16.39%66.23B7.49%231.98B8.47%174.61B6.15%111.71B
Operating income 6.14%209.63B5.14%139.41B5.93%70.15B12.21%260.3B13.11%197.51B18.70%132.59B16.39%66.23B7.49%231.98B8.47%174.61B6.15%111.71B
Operating expenses -7.44%-186.45B-6.67%-123.25B-7.87%-62.12B-13.63%-228.97B-14.22%-173.55B-19.50%-115.53B-16.19%-57.59B-7.59%-201.49B-9.10%-151.93B-5.98%-96.68B
Gross profit -3.28%23.18B-5.22%16.17B-7.03%8.03B2.76%31.33B5.67%23.96B13.51%17.06B17.80%8.63B6.81%30.49B4.45%22.68B7.26%15.03B
Selling expenses 9.46%-9.48B15.10%-6.57B15.86%-3.29B2.64%-13.9B-1.29%-10.47B-13.81%-7.73B-18.05%-3.91B-7.22%-14.28B-1.18%-10.34B-7.42%-6.79B
Administrative expenses 1.22%-4.14B-3.86%-2.87B-0.90%-1.39B-14.43%-5.71B-11.62%-4.19B-19.00%-2.76B-15.70%-1.38B2.95%-4.99B-5.09%-3.76B0.03%-2.32B
Research and development expenses -10.09%-1.62B-7.67%-1.11B7.26%-501.45M-4.35%-2.2B-5.70%-1.47B-26.76%-1.03B-20.82%-540.69M-6.29%-2.11B-1.63%-1.39B7.99%-809.67M
Profit from asset sales 39.44%145.83M88.91%139.31M405.21%110.04M-93.57%92.48M-92.67%104.58M-94.83%73.75M188.72%21.78M2,368.58%1.44B22,234.19%1.43B23,988.34%1.43B
Revaluation surplus -40.51%142.2M-41.94%114.29M-41.55%52.25M85.03%404.73M225.04%239.02M675.23%196.84M240.65%89.4M206.18%218.74M141.65%73.54M171.34%25.39M
-Changes in the fair value of other assets -40.51%142.2M-41.94%114.29M-41.55%52.25M85.03%404.73M225.04%239.02M675.23%196.84M240.65%89.4M206.18%218.74M141.65%73.54M171.34%25.39M
Impairment and provision -89.25%-496.97M-22.04%-329.78M-42.34%-241.8M-30.64%-841.24M-15.91%-262.6M-51.60%-270.22M-362.28%-169.87M-360.73%-643.93M13.13%-226.55M3.90%-178.24M
-Other impairment is provision -89.25%-496.97M-22.04%-329.78M-42.34%-241.8M-30.64%-841.24M-15.91%-262.6M-51.60%-270.22M-362.28%-169.87M-360.73%-643.93M13.13%-226.55M3.90%-178.24M
Special items of operating profit 96.95%682.34M124.15%384.1M-34.56%233.27M-21.78%725.04M-49.72%346.45M-61.50%171.36M41.47%356.49M-59.88%926.88M-67.03%689.04M-76.12%445.11M
Operating profit 1.40%7.82B3.86%5.54B-4.11%2.79B-11.38%9.15B-10.54%7.71B-17.32%5.33B23.59%2.91B9.28%10.33B11.48%8.62B11.00%6.45B
Financing cost 0.45%-1.15B8.70%-705.94M10.46%-374.43M-13.14%-1.49B-15.71%-1.15B-19.16%-773.22M-16.64%-418.18M-5.45%-1.31B-7.26%-997.59M-12.10%-648.91M
Special items of earning before tax 34.01%-24.39M63.46%-8.88M54.93%2.02M-197.11%-612.94M30.84%-36.96M41.10%-24.29M115.24%1.3M-234.51%-206.3M-1,031.28%-53.44M-228.25%-41.24M
Earning before tax 1.92%6.64B6.36%4.82B-3.02%2.42B-19.91%7.05B-13.86%6.52B-21.26%4.53B25.44%2.49B8.16%8.81B11.35%7.57B10.36%5.76B
Tax -3.57%-1.62B-9.66%-1.22B-2.28%-551.13M-3.93%-1.89B1.16%-1.57B6.45%-1.12B-18.63%-538.85M2.83%-1.82B-10.54%-1.58B-13.39%-1.19B
After-tax profit from continuing operations 1.40%5.02B5.28%3.6B-4.48%1.87B-26.11%5.17B-17.22%4.95B-25.14%3.42B27.46%1.95B11.43%6.99B11.56%5.98B9.59%4.56B
Earning after tax 1.40%5.02B5.28%3.6B-4.48%1.87B-26.11%5.17B-17.22%4.95B-25.14%3.42B27.46%1.95B11.43%6.99B11.56%5.98B9.59%4.56B
Minority profit -16.24%969.12M-18.80%655.45M-25.75%323.29M1.72%1.4B-1.14%1.16B-7.07%807.18M54.77%435.4M16.41%1.37B33.04%1.17B45.49%868.61M
Profit attributable to shareholders 6.78%4.05B12.72%2.94B1.62%1.54B-32.92%3.77B-21.13%3.8B-29.38%2.61B21.31%1.52B10.28%5.62B7.35%4.81B3.58%3.7B
Basic earnings per share 5.83%1.0911.27%0.792.44%0.42-36.65%1.02-28.97%1.03-37.17%0.71-6.82%0.41-10.06%1.61-8.23%1.45-10.32%1.13
Diluted earnings per share 5.83%1.0911.27%0.792.44%0.42-36.65%1.02-28.97%1.03-37.17%0.71-6.82%0.41-10.06%1.61-8.23%1.45-10.32%1.13
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ------Unqualified Opinion------Unqualified Opinion----
Auditor ------PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)------PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data